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Abstract  
BACKGROUND: Accurate assessment of HER-2 is imperative in selecting patients for targeted therapy. Most 
commonly used test methods for HER-2 are immunohistochemistry (IHC) and fluorescence in situ hybridisation 
(FISH). We evaluated the concordance between FISH and IHC for HER-2 in breast cancer samples using Food 
and Drug Administration approved tests. 
MATERIAL AND METHODS: Archived paraffin tissue blocks from 73 breast cancer patients were used. HER-2 
immunostaining was performed using Ventana anti–HER-2 monoclonal antibody. The FISH assay was performed 
using PathVysion™ HER-2 DNA Probe Kit. 
RESULTS: Of the 73 cases 68.5% were IHC 0/1+, 15.07% were IHC 2+ and 16.44% were IHC 3+. Successful 
hybridisation was achieved in 72 cases. HER-2 FISH amplification was determined in 16.67% cases. Ten IHC 3+ 
and two IHC 2+ cases were FISH positive. Two of the IHC 3+ cases were FISH negative. Concordance rate was 
100%, 18.18% and 83.33% for IHC 0/1+, 2+ and 3+ group, respectively. Total concordance was 84.72%, kappa 
0.598 (p < 0.0001). The sensitivity of IHC in detecting IHC 2+ and IHC 3+ cases was 16.7% and 83.3%, and the 
specificity was 85% and 96.67%, respectively. 
CONCLUSION: The consistency between the methods was highest for IHC negative and lowest for IHC 
equivocal cases. The immunohistochemistry showed high sensitivity for IHC 2+/3+ cases and high specificity for 
IHC 3+ cases. Our results support the view that false-positive rather than false-negative IHC results are a problem 
with HER-2/IHC testing, and that IHC should be used as an initial screening test, but IHC 2+/ 3+ results should be 
confirmed by FISH. 
 
 
 
 
Introduction 
 
The human epidermal growth factor receptor 
gene HER-2 (also known as HER-2/neu, c – erbB-2) 
is located on chromosome 17q12 and encodes a 
member of the epidermal growth factor receptor 
(EGFR) family with tyrosine kinase activity that is 
responsible for cell-cell or cell-stroma communication 
through the process of signal transduction [1]. 
Activation of the protein receptor is associated with 
increased cell proliferation, tumour invasiveness, 
progressive regional and distant metastases, 
increased angiogenesis and reduced apoptosis [1]. 
HER-2 gene amplification is the primary mechanism 
of protein overexpression and is found in nearly 15 to 
20% of breast cancer patients [1] [2]. HER-2 gene 
amplification or protein overexpression are molecular 
targets for specific targeted therapies associated with 
good results in early and metastatic HER-2 positive 
breast carcinomas [3] [4] [5]. Therefore, accurate 
assessment of HER-2, using reliable, highly sensitive 
and specific test is imperative in the selection of 
patients for the therapy [3] [4] [5]. 
To date, there is still no single, universally 
accepted test for HER-2 assessment. Two most 
commonly used techniques are immunohistochemistry 
(IHC) and in situ hybridisation (fluorescence in situ 
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hybridization-FISH and bright field in situ 
hybridization-BRISH), performed on formalin fixed 
paraffin embedded (FFPE) tissue samples [6] [7] [8]. 
Immunohistochemistry uses antibodies to detect HER-
2 protein expression on the surface of tumour cells, 
while FISH is a molecular method that uses 
fluorescently labelled DNA probes, to determine HER 
-2 gene copy number. Although both methods are 
widely used in the routine analysis, both have 
advantages and disadvantages. 
Immunohistochemistry is relatively cheap and fast 
method that uses the light microscope for analysis. 
Conversely, a FISH method is technically more 
demanding, time-consuming and expensive assay [9], 
but is more consistent and more objective [9]. 
Numerous studies that evaluated the consistency 
between the IHC and FISH, as well as their effect on 
the response to trastuzumab therapy, showed 
contradictory results [10]. 
In this study we evaluated the concordance 
between FISH and IHC for HER-2 assessment in 
breast cancer tissue samples, using Food and Drug 
Administration (FDA) approved tests. 
 
 
Material and Methods 
 
In this retrospective study, we used FFPE 
tissue blocks from 73 patients diagnosed with invasive 
breast carcinoma, non-special type (NST), during 
2014-2015. Patients who underwent radical 
mastectomy and did not receive neoadjuvant therapy 
were included. 
All the cases were stained and analysed in 
the standard procedure to determine the histologic 
type and grade of a tumour, lymph node status and 
the stage of the disease. Tumour grade was 
determined based on the recommendations of the 
Nottingham grading system [11], while the stage of 
the disease was determined according to the criteria 
of the American Joint Committee on Cancer (AJCC) 
[12]. The patients’ age and tumour dimension were 
obtained from medical records. HER-2/IHC was 
performed in parallel with ER, PR, and Ki-67 as part of 
the daily routine work at our Institute. Regardless of 
the IHC results, additional FISH testing was done in 
all cases, using parallel sections from the same tissue 
block as for IHC. 
Using 4 micron thick sections mounted on 
silanized microscopic slides, HER-2 immunostaining 
was performed on BenchMark GX automated staining 
instrument (Ventana Medical Systems, Inc., USA) 
using Ventana anti–HER-2 rabbit monoclonal primary 
antibody, clone 4B5 and UltraVIEW universal DAB 
Detection Kit (Ventana), according to the 
manufacturer’s recommendations. Briefly, after 
deparaffinization with EZ Prep, slides were pretreated 
with Cell Conditioning 1 for 36 minutes at 100°C and 
then incubated with anti–HER-2 primary antibody for 
20 minutes at 37°C. The antibody was detected using 
DAB and then counterstained with hematoxylin and 
bluing reagent, for 4 minutes in both steps. 
The ER, PR and Ki67 immunostainings were 
performed using DAKO monoclonal antibodies (clone 
EP1, dilution 1:50; clone PgR 636, dilution 1:100 and 
clone Mib1, dilution 1:150, respectively), by 
semiautomated PT Link immunoperoxidase 
technique. Shortly, after deparaffinization and 
rehydration, samples were pretreated using Target 
Retrieval Solution for 20 minutes at 97°C and then 
incubated with primary antibody for 20 minutes at 
25°C. Antibodies were detected using visualisation 
system (EnVision FLEX, DAKO) for 20 minutes at 
25°C and chromogen (di–amino-benzene-DAB) for 5 
minutes, also at 25°C. After that slides were 
counterstained with hematoxylin. 
Semiquantitative evaluation of HER-2 protein 
expression included evaluation of membrane positivity 
according to the criteria of American Society of 
Clinical Oncology (ASCO)/College of American 
Pathologists (CAP) [7]. The expression of ER, PR and 
Ki67 was evaluated as a percentage of positive cells 
of the total number of cells. One percent was the cut-
off point for hormone receptors [13], while 20% was 
taken as a cut-off point that distinguishes cases with 
low and high proliferative index (Ki67-low/Ki67-high) 
[14]. The slides were analyzed with a light 
microscope, Nikon 80i Eclipse (Nikon Instruments, 
Austria). 
The FISH assay was performed by using 
PathVysion™ HER-2 DNA Probe Kit (Abbott/Vysis, IL, 
USA) containing two fluorophore-labeled DNA probes 
allowing simultaneous detection of HER-2 and 
chromosome 17 (CEP 17) gene copy numbers: 
Spectrum Orange-labeled DNA probe for HER-2 gene 
locus and Spectrum Green labelled DNA probe for 
CEP 17. Samples were tested using two different 
paraffin pretreatment kits in two different FISH 
protocols, Vysis/Abbott Paraffin Pretreatment Reagent 
Kit (40 samples) and DAKO Histology FISH 
Accessory Kit (33 samples), described in details in a 
previous paper [15]. Briefly, 4 µm thick tumour 
sections were mounted on a positively charged 
microscopic slide, air dried and baked in the oven at 
56°C, overnight. After deparaffinization and 
pretreatment, slides were incubated with 
protease/pepsin. Then slides were washed, 
dehydrated and DNA probe was applied. After 
denaturation (5 minutes at 72°C) and hybridisation (16 
hours at 37°C), the slides were washed in preheated 
post-hybridisation buffer, counterstained with DAPI, 
and cover slips were applied. 
For accurate localisation of the invasive 
tumour component, the FISH assays were viewed in 
conjunction with H&E sections, and DAPI counterstain 
was used to identify tumour nuclei. Signals were 
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analyzed at x1000 magnification, using an appropriate 
filter. The results were interpreted according to 
recommendations of ASCO/CAP, where HER-2 status 
is defined as positive when the HER-2/CEP17 ratio is 
greater than 2, and negative when the ratio is less 
than 2 [7]. The tests were analysed using Olympus 
BX43 fluorescence microscope (Olympus 
Corporation, Japan) equipped with appropriate filters. 
Each case was photographed and documented with 
Olympus XM10 monochrome camera and analysed 
using the Olympus cell Sens Standard software, 
Version 1.15.  
Analyses were performed by using SPSS for 
Windows 17.0. The results of HER-2 status by FISH 
and IHC were compared, and concordance, 
sensitivity, specificity, negative and positive predictive 
values were evaluated considering FISH as the gold 
standard. Kappa test was used to determine the 
concordance between the methods. Also, Fisher’s 
exact two-tailed test and Chi-square tests were used 
to determine the correlation of HER-2 status with ER 
and PR status along with various clinical and histology 
parameters. The p-value < 0.05 was considered 
statistically significant. 
 
 
Results 
 
The HER-2/ IHC results showed that most of 
the samples 32 (43.84%), were classified as IHC 0, 
followed by 18 (24.66%) classified as IHC 1+, 12 
(16.44%) classified as IHC 3+ and 11 (15.07%) 
classified as IHC 2+ (Figure 1A). From 73 cases 
included in this study, 72 showed successful 
hybridisation. HER-2 FISH gene amplification was 
determined in 12 (16.44%) of the cases, while 60 
(82.19%) of the cases were FISH negative (Figure 1B 
and Figure 2). One case with failed hybridisation was 
excluded from the study. The FISH failure rate was 
1.37%. 
 
Figure 1: Distribution of HER-2 according to A, IHC (left) and B, 
FISH (right) 
 
Of 12 HER-2 FISH amplified cases, 10 
(83.3%) were scored IHC 3+, 2 (16.7%) were scored 
IHC 2+ and none was scored IHC 1+ or 0. Among the 
60 FISH-negative cases, only 2 (3.3%) had IHC score 
3+ (Figure 3), and the other samples were either 
indeterminate 9 (15%) or negative 49 (81.7%). The 
two IHC 3+ cases that were negative for FISH showed 
polysomy for chromosome 17.  
  A                                                  B 
 
Figure 2: Typical examples of FISH-positive and FISH negative 
case. A, FISH amplified case, HER-2/Chr 17 ˃ 2 (DAPI counterstain 
x 1000); B, FISH non amplified case, HER-2/Chr 17 < 2 (DAPI 
counterstain x 1000) 
 
In Table 1 we present the rate of concordance 
for HER-2 results obtained by IHC and FISH. The 
concordance rate was high (100%) for negative IHC 
0/1+ group and low (18.18%) for undetermined IHC 
2+ group. The concordance rate for IHC 3+ group was 
83.33%. 
 
Figure 3: Discordance between IHC and FISH in two cases. Case 1: 
A, Invasive breast carcinoma (H&E x 200); B, HER-2/IHC 3+ (HER-
2 x 200), C, FISH, HER-2/Chr 17 < 2, non amplified (DAPI 
counterstain x 1000). Case 2: D, Invasive breast carcinoma (H&E x 
200); E, HER-2/IHC 3+ (HER-2 x 200); F, FISH, HER-2/Chr 17 < 2, 
non-amplified (DAPI counterstain x 1000) 
 
When IHC 2+ and 3+ positive tumours were 
grouped, the total concordance between IHC and 
FISH was 84.72% (61/72), and the Kappa coefficient 
was 0.598, with a statistical significance of p < 0.0001. 
After excluding the IHC 2+ cases, the concordance 
rate improved to 96.72% (59/61). 
Table 1: Comparison of HER-2 results determined by IHC and 
FISH 
IHC scoring HER-2/FISH 
positive 
HER-2/FISH 
negative 
Concordance by IHC Discordance by 
IHC 
0/1+ (n=49) 0 49 (49/49) 100% (0/49) 0% 
2+ (n=11) 2 9 (2/11) 18.18% (9/11) 81.82% 
3+ (n=12) 10 2 (10/12) 83.33% (2/12) 16.67% 
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Table 2 presents the diagnostic performances 
of the IHC method in determining the HER-2 status 
using the FISH method as a gold standard. As 
indicated, the positive predictive value for positive IHC 
3+ cases was 83.3%, and for 2+/3+ cases was 52.2%. 
The immunohistochemical method showed the 
sensitivity of 100% and 83.3% in detecting IHC 2+/3+ 
and 3+ cases, and specificity of 81.67% and 96.7% in 
detecting IHC 2+/3+ and IHC 3+ cases, accordingly. 
Table 2: Sensitivity, specificity, positive and negative 
predictive values of IHC according to FISH as gold standard 
IHC scoring 
Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
PPV (%) 
(95% CI) 
NPV (%) 
(95% CI) 
2+/3+ positive 100(75.8-100) 81.67(70.1-89.4) 52.2(33.01-70.8) 100(92.7-100) 
3+ positive 83.3(55.2-95.3) 96.7(88.6-99.1) 83.3(55.2-95.3) 96.7(88.6-99.1) 
2+ positive 16.7(4.7-44.8) 85(73.9-91.9) 18.2(5.1-47.7) 83.6(72.4-90.8) 
 
In table 3 we present a correlation between 
HER-2 amplification and clinico-pathological 
characteristics. The mean age of the patients included 
in the study was 57.98 ± 10.3 years (range, 41-86 
years), and the mean tumour size was 27.01 ± 14.8 
mm (range, 8-75 mm). There was no significant 
correlation between HER-2 amplification and patients’ 
age, tumour size, tumour grade (G), nuclear grade 
(NG), tumour status (pT), lymph node status (pN) or 
stage of the disease. A significant correlation (p < 
0.05) was detected between HER-2 and biological 
markers (ER, PR, Ki 67). ER and PR were more 
commonly detected in the HER-2/FISH negative than 
in HER-2/FISH positive tumours (90% vs 58.33%; 
78.33% vs 41.67%, respectively). Conversely, the 
high proliferative index was more frequently found in 
HER -2 positive tumours (91.67% vs 56.67%). 
Table 3: Correlation of clinical and pathological features with 
HER-2 amplification status 
Variable Total 
n (%) 
HER-2/FISH p-value 
Negative (n = 
60) 
Positive (n = 12) 
Age ≤50 
>50 
23 (31.94) 
49 (68.06) 
17 (28.33) 
43 (71.67) 
6 (50) 
6 (50) 
0.18 
Tumor size (mm) ≤20 
>20 
24 (33.33) 
48 (85.42) 
19 (79.17) 
41 (85.42) 
5 (20.83) 
7 (14.58) 
0.5 
G 1 3 (4.17) 3 (5) 0 0.26 
2 19 (26.39) 18 (30) 1 (8.33) 
3 50 (69.44) 39 (65) 11 (91.67) 
NG 1 1 (1.39) 1 (1.67) 0 0.12 
2 15 (20.83) 15 (25) 0 
3 56 (77.78) 44 (73.33) 12 (100) 
pT 1 24 (33.33) 19 (31.67) 5 (41.67) 0.34 
2 41 (56.94) 35 (58.33) 6 (50) 
3 2 (2.78) 1 (1.67) 1 (8.33) 
4 5 (6.94) 5 (8.33) 0 
pN 0 27 (37.56) 24 (40) 3 (25) 0.13 
1 21 (29.17) 18 (30) 3 (25) 
2 12 (16.67) 11 (18.33) 1 (8.33) 
3 12 (16.67) 7 (11.67) 5 (41.67) 
Stage I 16 (22.22) 14 (23.33) 2 (16.67) 0.66 
II 30 (41.67) 26 (43.33) 4 (33.33) 
III 26 (36.11) 20 (33.33) 6 (50) 
ER N 11 (15.28) 6 (10) 5 (41.67) 0.015 
P 61 (84.72) 54 (90) 7 (58.33) 
PR N 20 (27.78) 13 (21.67) 7 (58.33) 0.016 
P 52 (72.22) 47 (78.33) 5 (41.67) 
Ki 67 high 45 (62.5) 34 (56.67) 11 (91.67) 0.025 
low 27 (37.5) 26 (43.33) 1 (8.33) 
 
G- histological grade, NG- nuclear grade, pT- 
tumour status, pN- lymph node status, ER- estrogen 
receptor, PR- progesterone receptor, Ki67- a marker 
of proliferation. 
Discussion 
 
Breast cancer is the most common malignant 
tumour and second leading cause of cancer death in 
women [16]. Prognosis and treatment of breast cancer 
patients depend on several factors, such as 
histological type, grade, stage, hormone receptor 
status and HER-2 status. Determination of HER-2 
status is a strong indicator of response to treatment 
with trastuzumab [17] [18]. Considering the benefits 
and side effects that patients would have from 
targeted therapy, the use of the appropriate test for 
HER -2 assessment is essential in selecting patients 
for treatment [3] [5]. Immunohistochemistry and FISH 
are most widely used routine test methods in 
pathology laboratories. Both methods have their 
advantages and disadvantages. To date, it is still 
under debate which single method is the best for 
HER-2 determination. According to some authors, the 
use of IHC and FISH methods in combination is the 
most effective strategy even though it is not cost 
effective [19] [20]. Immunohistochemistry is widely 
used, relatively inexpensive and easy to perform test 
method for HER-2. It is affected by variations in tissue 
fixation and processing and variations in testing 
methodologies that can influence the final results [21]. 
Other disadvantages of IHC are subjectivity in 
interpretation of the results and absence of internal 
control, which calls into question the reliability of the 
analysis, especially when the HER-2/IHC results are 
negative [3] [21] [22]. 
Fluorescence in situ hybridisation is 
expensive, technically demanding molecular assay 
that requires special equipment for evaluating the 
results, and its performance is limited to a smaller 
number of pathology laboratories [9]. However, the 
FISH method has several advantages over 
immunohistochemistry: it is less affected by artefacts 
associated with tissue processing, is more objective 
because the results are quantitative, and there are 
internal positive controls [9]. Fluorescence in situ 
hybridisation is a method of choice when selecting 
patients for HER-2 targeted therapy regarding 
accuracy, reproducibility, and predictivity [3]. It 
provides 96.5% sensitivity and 100% specificity for 
detection of HER-2 gene amplification in breast 
cancer patients [23]. 
In this study, we evaluated the concordance 
between FISH and IHC for HER-2 detection in breast 
cancer patients using FDA approved tests. Most of 
our cases (68.5%) were classified IHC 0/1+, 16.44% 
were classified IHC 3+ and 15.07% were classified 
IHC 2+. None of IHC 0/1+ cases was FISH positive. 
16.67% of cases in our study showed amplification for 
HER-2: two cases of IHC 2+ group were FISH 
positive, and two cases from IHC 3+ group were FISH 
negative. Concordance rate in our study was 100%, 
18.18% and 83.33% for IHC 0/1+, 2+ and 3+ group, 
respectively. When 2+ and 3+ positive tumours were 
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grouped together, the concordance rate between IHC 
and FISH was 84.72%, kappa 0.598 (p < 0.0001), but 
after excluding the IHC 2+ cases form the group, the 
total concordance rate improved to 96.72%. According 
to literature, concordance rate between IHC and FISH 
ranges from 79% to 100% for 3+ cases [24] [25] and 
from 12% to 36% for 2+ cases [26] [27]. 
Gokhale et al., [10] showed high concordance 
between FISH and IHC 3+ groups and poor 
concordance in the 0, 1+ and 2+ groups. Contrary to 
these results, other authors [28] [29] have shown that 
the concordance rate between IHC and FISH is 
highest for the IHC negative cases and lowest for the 
IHC 2+ and 3+ cases. Our results also confirmed high 
concordance rate in IHC 0/1+ group, followed by IHC 
3+ group with the lowest concordance rate in the IHC 
2+ group. Other authors reported low concordance 
rates of only 51% between IHC and FISH [21] owing 
to subjectivity in interpretation, chromosome 17 
aneuploidy and technical aspects of tissue processing 
and IHC. Sarode et al. [30] showed significant 
improvement in concordance rate in 10 year period 
due to an overall improvement in standardisation of 
pre-analytic and analytic variables and experience in 
HER-2 scoring. The finding of IHC 3+ staining without 
gene amplification is attributed to false -positive 
immunostaining when using an unstandardized or 
unvalidated immunohistochemical method, or 
chromosome 17 polysomy [31] [32]. Several studies 
have shown that chromosome 17 polysomy is 
responsible for discrepancies between protein 
expression and gene ampliﬁcation [23] and that these 
patients have similar clinical outcomes to patients 
without the HER-2 gene alteration. The rate of 
discordance in our study may be the result of 
variability in tissue fixation (time to fixation and time in 
fixative) because almost half of the cases included 
were from other city hospitals where tissue fixation 
started. However, we cannot exclude the influence of 
aneusomy 17 because two IHC 3+/FISH- cases in our 
study, showed chromosome 17 polysomy.  
Taking the FISH method as a gold standard, 
sensitivity rate in our study was 16.7% and 83.3% for 
IHC 2+ and 3+ cases. The specificity rate was 96.67% 
and 85% for 3+ and 2+ cases, respectively. When 
2+/3+ cases were analyzed as a group, the sensitivity 
was 100%, but the specificity was 81.67%. The 
positive predictive value of positive IHC 3+ and IHC 
2+/3+ cases was 83.3% and 52.2% respectively, and 
negative predictive value for negative IHC 0/1+ cases 
was 100%. The immunohistochemical method 
showed the highest sensitivity of 100% in detecting 
IHC 2+/3+ positive tumours as one group. Other 
authors reported high specificity (94%), but low 
sensitivity (43%), of immunohistochemistry [10]. 
According to some authors, the lowest cost -
effective HER-2 testing is to screen all breast cancer 
patients with immunohistochemistry (because of its 
high negative predictive value) and to confirm only 
IHC 2+ and 3+ scores with the FISH assay [29]. 
Although FISH testing is much more expensive than 
IHC, it never exceeds the cost of treating patients who 
are not likely to beneﬁt because of a false-positive 
IHC [29]. Our ﬁndings support the view that false -
positive rather than false-negative IHC results are a 
major issue with HER-2 IHC testing. HER-2 positive 
status is a bad prognostic marker, and these tumours 
are associated with high histological grade, negative 
hormone receptor status and positive regional lymph 
nodes at the time of diagnosis [30] [33] [34]. Our 
results did not show a significant correlation between 
HER-2 amplification and other clinico-pathological 
parameters like patient’s age, tumour size, tumour 
grade, nuclear grade, lymph node status and stage of 
the disease. Although statistically non-significant 
HER-2 amplified, tumours were more frequently 
poorly differentiated with high nuclear grade, positive 
lymph node status and high postoperative stage 
indicating biologically more aggressive tumours. Other 
authors found no association between HER-2 and 
patients age [35] [36] [37] [38] tumor size [35] [36] [37] 
or lymph node status [35], too. Contrary to our results, 
other authors noted significant correlation of HER-2 
with tumour size [39] tumour grade [35] [39] or lymph 
node metastasis [40] [41]. 
Statistically significant association in our study 
was detected between HER-2 positive tumors and 
negative estrogen (p = 0.015), progesterone receptor 
(p = 0.016) status, and high proliferative index Ki67 (p 
= 0.025). Some authors also reported significant 
correlation with negative hormone receptor status [35] 
[39] and high proliferative index [30] [37] [38], while 
other authors showed correlation with positive 
hormone receptor status [41] [42] or low Ki67 [41]. 
In conclusion, the overall concordance 
between IHC and FISH was 84.72%. The consistency 
between the two methods was highest for IHC 
negative and lowest for IHC equivocal cases. With 
FISH as the gold standard, the positive predictive 
value of positive (IHC 3+) cases was 83.3%, and 
negative predictive value for negative (IHC 0/1+) 
cases was 100%. The immunohistochemical method 
showed high sensitivity in IHC 2+/3+ cases and high 
specificity in IHC 3+ group. Our results support the 
view that false -positive rather than false-negative IHC 
results are a bigger problem with HER-2/IHC testing, 
and that IHC should be used as an initial screening 
test, but that FISH should confirm IHC 2+ and 3+ 
results. Standardization of tissue processing is 
necessary to improve the specificity of the IHC assay.  
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